CABA-201, at lower testing doses, showed slower kinetics of CD19+ tumor cell line control than FMC63 CAR T cells; however, CABA-201 cells equally controlled the tumor growth by the end of the study period, and this slower kinetics was not observed in two independent experiments at a higher dose. The gene discussed is CD19; the disease is neoplasm.